IODINE-131 META IODOBENZYLGUANIDINE DIN 02349515
Status: Cancelled Pre Market
Holder: EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES)
Molecule: IOBENGUANE
Health Canada record
| Active ingredient(s) | IOBENGUANE 131I 375 MBq |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | |
| Original market date | |
| Current status date | 09-Jun-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Edmonton Radiopharmaceutical Centre (Alberta Health Services) — licence 100014, currently licensed, last inspection rating C (2026-06-01).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing IOBENGUANE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02387034 | ADREVIEW | GE HEALTHCARE CANADA INC | Solution | IOBENGUANE 123 I 74 MBq | Marketed |
| 02349493 | IODINE-123 META IODOBENZYLGUANIDINE | EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES) | Solution | IOBENGUANE 123 I 185 MBq | Cancelled Pre Market |